Tissue specificity of 8-prenylnaringenin:: Protection from ovariectomy induced bone loss with minimal trophic effects on the uterus

被引:47
作者
Hümpel, M
Isaksson, P
Schaefer, O
Kaufmann, U
Ciana, P
Maggi, A
Schleuning, WD
机构
[1] Res Labs Schering AG, D-13342 Berlin, Germany
[2] Leiras Oy Biomed Res Ctr, Turku 20101, Finland
[3] Univ Milan, Ctr Neurodegenerat Dis, I-20133 Milan, Italy
[4] Noxxon Pharma AG, D-10589 Berlin, Germany
关键词
8-prenylnaringenin; phyto-estrogen; tissue specific estrogenicity; HRT; osteoporosis;
D O I
10.1016/j.jsbmb.2005.05.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plant secondary metabolites with estrogenic activity (phyto-estrogens) have been studied in the past as a potential alternative to classical hormone-replacement therapy (HRT) in menopausal women. No final verdict on the efficacy of soy or red clover based pharmaceutical preparations has been reached despite numerous clinical studies. We have studied the novel and most potent phyto-estrogen 8-prenylnaringenin (8-PN) in adult ovariectomized rats, an established animal model to mimic hormone dependent osteoporosis in menopausal women. Our results demonstrate that 8-PN can completely protect from ovariectomy induced bone-loss while exhibiting minimal, (dose independent) trophic effects on uterus and endometrium. It is estimated that at equivalent bone protective doses of 17 beta-estradiol and 8-PN, the phyto-estrogen has a 10-fold lower stimulatory effect on uterus and endometrium. The bone tissue specific effect of 8-PN was confirmed in a transgenic reporter mouse model (ERE-Luc mice). Here we also found pronounced estrogenic activity in prostate. Present results add important aspects to the pharmacological profile of 8-PN and position this compound as an interesting alternative new candidate for treatment of peri- and postmenopausal symptoms. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:299 / 305
页数:7
相关论文
共 23 条
[1]  
Bennetts H. W., 1946, AUSTRALIAN VET JOUR, V22, P2, DOI 10.1111/j.1751-0813.1946.tb15473.x
[2]   Engineering of a mouse for the in vivo profiling of estrogen receptor activity [J].
Ciana, P ;
Di Luccio, G ;
Belcredito, S ;
Pollio, G ;
Vegeto, E ;
Tatangelo, L ;
Tiveron, C ;
Maggi, A .
MOLECULAR ENDOCRINOLOGY, 2001, 15 (07) :1104-1113
[3]   Dietary phytoestrogens and health [J].
Cornwell, T ;
Cohick, W ;
Raskin, I .
PHYTOCHEMISTRY, 2004, 65 (08) :995-1016
[4]   A comparison of transcriptional activation by ERα and ERβ [J].
Cowley, SM ;
Parker, MG .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 69 (1-6) :165-175
[5]   Soy isoflavones: hope or hype? [J].
Fitzpatrick, LA .
MATURITAS, 2003, 44 :S21-S29
[6]   An efficient synthesis of the potent phytoestrogens 8-prenylnaringenin and 6-(1,1-dimethylallyl)naringenin by europium(III)-catalyzed Claisen rearrangement [J].
Gester, S ;
Metz, P ;
Zierau, O ;
Vollmer, G .
TETRAHEDRON, 2001, 57 (06) :1015-1018
[7]   What pharmacologists can learn from recent advances in estrogen signalling [J].
Gustaftson, JÅ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (09) :479-485
[8]   The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens [J].
Hall, JM ;
McDonnell, DP .
ENDOCRINOLOGY, 1999, 140 (12) :5566-5578
[9]   Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements [J].
Hall, JM ;
McDonnell, DP ;
Korach, KS .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (03) :469-486
[10]   Effects of estrogen plus progestin on health-related quality of life [J].
Hays, J ;
Ockene, JK ;
Brunner, RL ;
Kotchen, JM ;
Manson, JE ;
Patterson, RE ;
Aragaki, AK ;
Shumaker, SA ;
Brzyski, RG ;
LaCroix, AZ ;
Granek, IA ;
Valanis, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1839-1854